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A B S T R A C T   
While high levels of glucocorticoids are generally neuro-damaging, a related adrenal steroid, dehydroepian-
drosterone (DHEA), has anti-glucocorticoid and neuroprotective properties. Previous work has shown increased 
circulating levels of DHEA and abnormal cortisol/DHEA ratios in people with schizophrenia, however reports are 
limited and their relationship to neuropathology is unclear. We performed the largest study to date to compare 
levels of serum DHEA and cortisol/DHEA ratios in people with schizophrenia and healthy controls, and inves-
tigated the extent to which cortisol/DHEA ratios predict brain volume. Serum cortisol and DHEA were assayed in 
94 people with schizophrenia and 81 healthy controls. T1-weighted high-resolution anatomical scans were ob-
tained using a 3 T Achieva scanner on a subset of 59 people with schizophrenia and 60 healthy controls. Imaging 
data were preprocessed and analyzed using SPM12. People with schizophrenia had significantly increased serum 
DHEA levels (p = 0.002), decreased cortisol/DHEA ratios (p = 0.02) and no difference in cortisol levels compared 
to healthy controls. Cortisol/DHEA ratios were inversely correlated with hippocampal (r = -0.33 p = 0.01) and 
dorsolateral prefrontal cortex (r = -0.30, p = 0.02) volumes in patients. Our findings suggest that the cortisol/ 
DHEA ratio may be a molecular blood signature of hippocampal and cortical damage. These results further 
implicate the role of DHEA and hypothalamic-pituitary-adrenal axis dysfunction in the pathophysiology of 
schizophrenia.   
1. Introduction 
Clinical and biological data indicate impaired biological response to 
stress in people with schizophrenia (Walker and Diforio, 1997), which is 
associated with dysregulation of the hypothalamic-pituitary-adrenal 
(HPA) axis (Ciufolini et al., 2014) and alterations in cortical stress 
response molecules (Sinclair et al., 2011; Webster et al., 2002). High 
levels of glucocorticoids induce neurotoxicity, atrophy, inhibition of 
neurogenesis and neuronal death (Sapolsky et al., 1985). Increased 
corticosteroids are associated with structural changes (usually decreased 
volume) in the hippocampus (Sapolsky et al., 1990) and prefrontal 
cortex (Carrion et al., 2010). The hippocampus and prefrontal cortex are 
principal targets for glucocorticoids where molecular abnormalities in 
glucocorticoid responses have been identified in individuals with 
schizophrenia (Sinclair et al., 2011; Webster et al., 2002) and where 
brain volume reductions have been repeatedly reported (Gur et al., 
2000; Nelson et al., 1998). Circulating glucocorticoids, such as cortisol, 
have been linked to hippocampal volumetric reductions in people with 
first episode psychosis, demonstrating the deleterious effects of stress 
early in the illness (Mondelli et al., 2010b). 
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Studies of cortisol alone do not take into account the role of other 
regulatory hormones in the HPA axis in mediating or attenuating the 
adverse effects of glucocorticoids. In humans, cortisol and dehydro-
epiandrosterone (DHEA) are co-synthesized and released by the adre-
nal glands via adrenocorticotropic hormone stimulation in response to 
stress. DHEA has multiple neuroprotective effects on the central ner-
vous system. DHEA protects neurons against glutamate and beta 
amyloid-protein toxicity (Cardounel et al., 1999) and against insults 
resulting from oxidative stress (Bastianetto et al., 1999). DHEA en-
hances myelination and synaptogenesis, and stimulates the growth of 
neurons in the central nervous system (Friess et al., 2000). DHEA 
readily crosses the blood-brain barrier and levels of DHEA in the blood 
and cerebrospinal fluid (CSF) are strongly correlated (Kancheva et al., 
2011), thus changes in circulating levels of DHEA may be especially 
pertinent to brain health. Studies have generally reported increased 
levels of DHEA in individuals with schizophrenia relative to healthy 
people (di Michele et al. 2005; Ritsner et al., 2006; Strous et al., 2004), 
although decreased DHEA (Tourney and Hatfield, 1972) and no dif-
ference in (Ritsner et al., 2004) DHEA levels have also been found. 
Despite varying reports regarding circulating levels, owing to its 
properties, it is speculated that DHEA serves as a protective or 
compensatory mechanism in the disease (Strous et al., 2004). In sup-
port of this, there is evidence for an inverse relationship between levels 
of DHEA-sulfate and symptom severity (depressive and negative 
symptoms) early on in the disease (Garner et al., 2011), although this 
relationship was not found in chronically ill people with schizophrenia 
(Ritsner et al., 2004). 
Owing to the anti-glucocorticoid properties of DHEA, the cortisol/ 
DHEA ratio has been considered an indicator of the functional state of 
HPA axis activity and may therefore be more informative than the ab-
solute concentrations of either cortisol or DHEA alone (Wolkowitz et al., 
2001). Previous research suggests that the ratio of cortisol/DHEA found 
in the peripheral blood may be increased in people with schizophrenia 
(Ritsner et al., 2004), however some studies have found no difference in 
the cortisol/DHEA ratio compared to healthy people (Gallagher et al., 
2007; Garner et al., 2011). There are findings that cortisol/DHEA-sulfate 
ratios are positively correlated with positive and negative symptoms 
(Garner et al., 2011) as well as with depressive symptoms (Garner et al., 
2011; Ritsner et al., 2004) in schizophrenia. The finding of a relationship 
between cortisol/DHEA-sulfate and negative symptom severity in peo-
ple with first-episode psychosis suggests that illness chronicity and an-
tipsychotics may not be contributing factors in the relationship (Garner 
et al., 2011). While previous studies have assessed the relationship of 
cortisol/DHEA ratio to behavioral phenotypes, no study to date has 
investigated whether cortisol/DHEA ratios are associated with under-
lying biological changes such as neuroanatomical abnormalities. As the 
co-release of cortisol and DHEA in response to acute stress protects cells 
against the damaging effects of hypercortisolemia, the cortisol/DHEA 
ratio may be useful in examining stress-induced morphological changes 
in the brain. 
Thus, the aims of the present study were, firstly, to compare serum 
cortisol, DHEA levels and cortisol/DHEA ratios in people with 
schizophrenia and healthy controls and, secondly, to examine whether 
the latter index predicts brain volume. We selected the hippocampus 
and prefrontal cortex as regions of interests (ROI) for our brain volume 
analysis as they are vulnerable targets of stress (Carrion et al., 2010; 
Mondelli et al., 2010b; Sapolsky et al., 1990) and regulate negative 
feedback of the HPA axis via their glucocorticoid receptors (Diorio 
et al., 1993; Jacobson and Sapolsky, 1991). On the basis of studies 
suggesting that DHEA may play a compensatory role in schizophrenia 
(di Michele et al., 2005; Strous et al., 2004), we hypothesized that 
patients in our study would display increased circulating levels of 
DHEA compared to controls. However, due to cortisol variation in 
schizophrenia (both upregulation and downregulation/blunted 
response due to HPA axis abnormalities (Jansen et al., 2000; Mondelli 
et al., 2010a)), our comparative analysis of serum cortisol and 
cortisol/DHEA ratios in schizophrenia patients versus healthy people 
was exploratory and therefore, we had a non-directional hypothesis 
concerning a potential direction of change. Lastly, we predicted that 
the cortisol/DHEA ratio would be negatively correlated with brain 
volume in people with schizophrenia, such that increased DHEA 
would buffer against the negative effects (e.g. brain atrophy) of 
chronic stress. 
2. Materials and Methods 
2.1. Participants 
Ninety-four outpatients with schizophrenia or schizoaffective disor-
der and 81 healthy controls 18-51 years of age were included in the 
present study and were recruited to one of two sites: Sydney (Neuro-
science Research Australia in Sydney, NSW, Australia) or Adelaide (Lyell 
McEwen Hospital in Adelaide, Australia). Patients were recruited from 
local clinics and via a national television program on schizophrenia 
research. Diagnoses were confirmed by clinical interview by a psychi-
atrist or psychologist using the Structured Clinical Interview for DSM-IV. 
All patients had been receiving antipsychotics for at least 1 year before 
their entry into the study (see Table S1 for numbers of patients receiving 
a single antipsychotic or a combination). Patients with a concurrent Axis 
I diagnosis, head injuries with loss of consciousness, seizures, recent 
history of alcohol and/or substance abuse/dependence (within past 5 
years), a central nervous system infection, uncontrolled diabetes or 
hypertension, structural brain abnormalities, mental retardation or a 
learning disability were excluded. Additionally, females were excluded 
if they were currently pregnant or if they were receiving hormone 
therapy and refused alternate forms of birth control. Symptom severity 
in participants with schizophrenia was evaluated with the Positive and 
Negative Syndrome Scale (PANSS). Positive, negative, general psycho-
pathology and total symptom severity scores were calculated. Inter-rater 
reliability was established with an average intraclass correlation coef-
ficient of 0.90. Healthy control subjects were recruited through adver-
tising. Healthy people with a personal history or first-degree relative 
with DSM-IV Axis I psychiatric diagnosis, history of a head injury with 
loss of consciousness, seizures, recent history of alcohol and/or sub-
stance abuse/dependence (within the past 5 years), a central nervous 
system infection, uncontrolled diabetes or hypertension, structural brain 
abnormalities, mental retardation or a learning disability were 
excluded. All participants were assessed with a four subtest version of 
the Wechsler Adult Intelligence scale, 3rd edition (WAIS-III) comprised 
of the Arithmetic, Digit Symbol, Similarities and Picture Completion 
subtests as an estimate of current IQ. 
The protocol was approved by the Human Research Ethics Com-
mittees from the University of New South Wales and the South Eastern 
Sydney and Illawarra Area Health Service in Sydney, and the Queen 
Elizabeth Hospital, Adelaide, South Australia. All subjects provided 
written informed consent prior to participation in this study. 
2.2. Serum collection and laboratory analyses 
Fasting peripheral blood was collected from participants between 
0900 and 1100 h to control for alternations in hormone levels due to 
circadian variations. Blood samples were put on ice and stored at −80 ◦C 
until assayed. Serum cortisol levels were assayed by South Eastern Area 
Laboratory Services in Randwick, NSW, Australia using a chemilumi-
nescent immunometric assay (Siemens Immulite 2000). Serum DHEA 
levels were analyzed by the ANZAC Research Institute, Concord Hos-
pital, NSW, Australia with liquid chromatography–mass spectrometry 
(LC-MS) analysis (Harwood and Handelsman, 2009). The limits of 
detection for assays were 27.6 nmol/L for cortisol and 0.05 ng/ml for 
DHEA. The intra-assay coefficients of variations were < 10%. DHEA was 
converted to nmol/L to standardize units of measurement prior to 
computing cortisol/DHEA ratios. 
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2.3. Structural MRI acquisition and processing 
Only a subset of participants received magnetic resonance imaging 
(MRI) scans (n = 121, Sydney site only). Structural MRI scans were 
acquired using a 3-Tesla Phillips Achieva scanner with an 8-channel 
bird-cage type head coil at Neuroscience Research Australia, Rand-
wick, NSW, Australia. Each participant received a T1-weighted high- 
resolution anatomical scan (TR: 5.4 ms; TE: 2.4 ms; FOV: 256 mm; 
matrix: 256 × 256; sagittal plane; slice thickness: 1 mm, no gap; 180 
slices). 
All scans were processed and analysed using the VBM8 toolbox (htt 
p://www.neuro.uni-jena.de/vbm) implemented in Statistical Para-
metric Mapping software (SPM12; http://www.fil.ion.ucl.ac.uk/spm) 
running under MATLAB version 2012b. The T1-weighted images were 
segmented into tissue classes of grey matter, white matter and cere-
brospinal fluid. Following this, a high-dimensional DARTEL normali-
zation was performed for optimal registration of individual segments to 
a group mean template. The voxel-based morphometry analysis was 
restricted to differences in grey matter; therefore, the resulting grey 
matter volume segments were modulated by the Jacobian determinants 
to correct for local volume changes introduced by normalization. 
Finally, the DARTEL-normalized modulated grey matter segments were 
smoothed using an 8 mm full-width at half-maximum Gaussian kernel. 
Homogeneity using covariance was performed on the entire sample to 
help identify outliers, followed by visual inspection for artifacts, which 
resulted in the removal of two participants’ scans, yielding a total of 60 
healthy controls and 59 patients who were included in imaging analyses. 
The hippocampus and prefrontal cortex were chosen as our two a 
priori regions of interest (ROI), for comparative and correlational ana-
lyses. An ROI mask of the bilateral hippocampus was created and 
defined by the Automated Anatomic Labelling system in WFU PickAtlas, 
dilated x1. An ROI mask of the bilateral DLPFC was created by 
combining Brodmann areas 9 and 46 using WFU PickAtlas (http://fmri. 
wfubmc.edu/software/pickatlas), dilated x1. The masks created in WFU 
Pick Atlas were resliced from the default 2 × 2x2 voxel dimension to 1.5 
× 1.5 × 1.5 voxels in order to match the dimension of DARTEL- 
processed images. Using the segmented, normalized and modulated 
images, ROI grey matter volumes were obtained using get_totals.m 
Matlab script (Ged Ridgway; http://www0.cs.ucl.ac.uk/staff/g.ridgwa 
y/vbm/get_totals.m) with a signal threshold ≥ 0.1. Total intracranial 
volume (TIV), which was used as a covariate, was calculated by adding 
up the native space volumes of the grey matter, white matter and ce-
rebrospinal maps using the Tissue Volumes tool. 
2.4. Data Analysis 
Antipsychotic dose was converted to mean daily chlorpromazine 
(CPZ) equivalent dose based on standard guidelines (Woods, 2003). 
Group differences between healthy controls and patients in relation to 
continuous demographic variables were assessed using 2-sample t-tests 
(2-tailed) and differences in categorical variables were determined using 
Chi-squared tests. Raw DHEA, cortisol and cortisol/DHEA values were 
normalized through log10 transformation and no outliers were detected 
(> 3 standard deviations from mean). Using partial correlations with age 
as a covariate, we determined whether DHEA and cortisol levels were 
correlated in diagnostic groups, separately, and determined whether 
antipsychotic dose was associated with DHEA levels in patients. We 
assessed whether age of onset was related to DHEA or cortisol/DHEA 
levels using Pearson’s correlations and assessed whether duration of 
illness was related to DHEA or cortisol/DHEA using partial correlations, 
controlling for age. We also performed partial correlations in 83 pa-
tients, while controlling for age, between body mass index (BMI), as an 
indicator of metabolic syndrome (Fisher et al., 2019), and hormones, 
based on the observations that (1) the prevalence of metabolic syndrome 
is higher among individuals with schizophrenia as compared with 
healthy individuals (De Hert et al., 2009), (2) the prevalence of 
metabolic syndrome increases following antipsychotic use (Mitchell 
et al., 2013), (3) steroid hormones may regulate metabolic syndrome 
(Regelson and Kalimi, 1994), and (4) DHEA-sulfate serum levels are 
related to metabolic syndrome in acutely psychotic females (Boiko et al., 
2020). 
Our first aim was to compare serum cortisol, DHEA, and cortisol/ 
DHEA ratios between people with schizophrenia and healthy controls 
while controlling for potential confounders (age and sex). For our initial 
model, we entered each hormone and their ratio as dependent variables 
in separate linear mixed models using the lme4 package (Bates et al. 
(2015)) in R (R Core Team, 2017) including fixed effects for diagnosis 
(healthy control/schizophrenia), age, sex, an interaction of sex x diag-
nosis and random intercepts for each site (Sydney/Adelaide): Hormonei 
= Intercept + β1*Diagnosis + β2*Age + β3*Sex + β4*Sex*Diagnosis +
random effect (site). To assess whether similar findings exist within the 
subset of participants from the Sydney site who underwent scanning, we 
also compared hormone levels between this subset of patients and 
controls. 
Our second aim was to determine the extent to which cortisol/DHEA 
ratios predict brain volume. In SPM12, we compared brain volumes 
between patients and controls, restricted to the hippocampus and DLPFC 
using explicit masks, with age and TIV as nuisance parameters. Results 
were generated using a family-wise error rate (FWE) correction with a p 
< 0.05 at the cluster-level. Hippocampal and DLPFC volumes were used 
in partial correlation analyses with cortisol, DHEA and cortisol/DHEA 
ratios in controls and patients separately, while covarying for age. 
Pearson’s correlations were performed between mean daily CPZ equiv-
alent dose and ROI volumes to investigate the potential effects of anti-
psychotics on brain tissue changes. 
3. Results 
Regarding the overall sample, demographics of patients and controls 
and clinical characteristics of patients are presented in Table 1. The 
patients showed mild to moderate symptom severity based on the 
PANSS scores. There was a significant difference in age and expected 
significant differences in education and IQ between groups in which 
healthy controls were slightly younger (by ~4 years), received more 
Table 1 
Demographic Variables and Characteristics of the Whole Sample.   
Controls 
(n = 81) 
Schizophrenia 
(n = 94)    
Mean (SD) Mean (SD) t/ 
X2 
p-value 
Age (years) 31.8 (8.4) 35.7 (8.5) 3.0 0.003 
Education (years) 14.6 (2.2) 12.4 (2.3) 6.5 <
0.001 
Sex (number)   2.2 0.14 
Male 41 58   
Female 40 36   
Ethnicity (number)   5.4 0.25 
Caucasian 65 81   
Asian 10 5   
Caucasian-Asian 2 5   
Other 4 2   
WAIS-III FSIQ 107.3 (14.9) 91.0 (12.7) 7.8 <
0.001 
Age of onset (years)  22. 7 (5.6)   
Illness duration (years)  13.0 (7.6)   
Daily CPZ equivalents 
(mg)  
555.5 (470.0)   
PANSS positive  15.0 (4.7)   
PANSS negative  14.3 (6.2)   
PANSS general  30.7 (8.9)   
PANSS total  60.0 (16.9)   
Abbreviations: CPZ, chlorpromazine; F, Female; M, male; PANSS, Positive and 
Negative Syndrome Scale; WAIS-III FSIQ, Wechsler Adult Intelligence Scale III 
full-scale IQ estimate 
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years of education and had a higher (by 16 points) estimated IQ score 
relative to patients. There were no significant differences in relation to 
the sex or ethnicity ratios between the groups. 
Demographics of the subset of participants included in MRI analyses 
are presented in Table S2. Similar to the whole sample of 94 patients and 
81 controls, we found significant differences in age and education such 
that scanned controls were on average ~4.5 years younger than scanned 
patients, received more years of education and had a higher IQ (by 17 
points), and we found that the individuals in the subsample did not 
differ on any demographic, symptomatic or hormonal values as 
compared the total sample. 
Neither sex nor sex x diagnosis interaction were significant pre-
dictors of any hormones (all p > 0.1), while we found significant effects 
of age on serum DHEA, cortisol and cortisol/DHEA (p < 0.001, p =
0.006, p = 0.009, respectively). Consequently, we used age as a covar-
iate in all analyses related to hormones and our final model was as 
follows: Hormonei = Intercept + β1*Diagnosis + β2*Age + random ef-
fect (site). 
3.1. Elevated DHEA levels and decreased cortisol/DHEA ratios in people 
with schizophrenia 
Linear mixed models revealed significantly elevated serum DHEA 
levels in patients relative to healthy controls (t = 3.13, df = 171.3, p =
0.002, R2 = 0.17), see Fig. 1. There was no significant difference in 
serum cortisol levels between diagnostic groups (t = 0.63, df = 172.0, p 
= 0.53, R2 = 04). Cortisol/DHEA ratios were significantly decreased in 
people with schizophrenia as compared with healthy controls (t = 2.47, 
df = 171.2, p = 0.02, R2 = 0.12). 
Serum cortisol and DHEA levels were positively correlated in healthy 
controls (r = 0.23, p = 0.04) and were even more significantly and 
positively correlated in patients with schizophrenia (r = 0.43, p <
0.001). DHEA levels were not related to mean daily CPZ equivalents 
dose (r = -0.06, p = 0.55) in patients. Age of onset was not associated 
with DHEA (r = -0.07, p = 0.50) or cortisol/DHEA (r = 0.13, p = 0.22). 
Likewise, illness duration was not associated with DHEA (r = -0.18, p =
0.08) or cortisol/DHEA, controlling for age (r = 0.04, p = 0.73). Pa-
tients’ BMI was not associated with their serum DHEA (r = -0.01, p =
0.94) or cortisol (r = -0.13, p = 0.23) levels. 
Within the subsample of participants who underwent MRI scanning, 
we also found that patients displayed significantly elevated serum DHEA 
levels (t = 3.03, p = 0.003) and decreased cortisol/DHEA (t = 1.96, p =
0.05) compared to healthy controls. 
3.2. Cortisol/DHEA ratios are negatively correlated with brain volume in 
patients 
People with schizophrenia showed significant grey matter volume 
reductions relative to healthy controls in the hippocampus and DLPFC, 
FWE corrected at p < 0.05 (see Table S3). Cortisol/DHEA ratios were 
significantly, negatively correlated with hippocampal (r = -0.33, p =
0.01, df = 56) and DLPFC (r = -0.30, p = 0.02, df = 56) volume in pa-
tients (see Fig. 2). In contrast, cortisol/DHEA ratios showed no signifi-
cant correlations with hippocampal (r = -.01, p = 0.93, df = 57) or 
DLPFC (r = -.08, p = 0.54, df = 57) volume in healthy controls. There 
was a near-significant positive correlation (r = 0.26, p = 0.05, df =56) 
between DHEA and hippocampal volume in patients. There were no 
significant correlations between ROI volumes and serum cortisol or 
DHEA levels alone in either group (Table S4). Mean daily CPZ equivalent 
dose was not associated with brain volume of either ROI (hippocampus: 
r = -0.05, p = 0.73; DLPFC: r = -0.12, p = 0.36). 
4. Discussion 
The key findings from the present study include: (1) significantly 
elevated serum DHEA levels in patients relative to controls; (2) signifi-
cantly decreased cortisol/DHEA ratios in patients relative to controls; 
and (3) significant inverse relationships of cortisol/DHEA ratios to 
hippocampal and DLPFC volumes in patients after adjustment for age. 
Although it was not a primary aim of the present study, we also repli-
cated well-established reports of hippocampal and DLPFC volume 
reduction in people with schizophrenia (Nelson et al., 1998; Selemon 
et al., 2002). 
Our finding of elevated DHEA levels in the patient cohort is in 
agreement with other studies measuring DHEA in the periphery (di 
Michele et al., 2005; Ritsner et al., 2006; Strous et al., 2004) and in 
postmortem brain tissue (Marx et al., 2006) in people with schizo-
phrenia. One study reported higher levels of DHEA-sulfate at first onset 
of psychosis but not in subsequent episodes (Beyazyüz et al., 2014), so 
they speculated that DHEA(S) levels diminish with chronic illness. 
However, we found significantly elevated DHEA levels in people with 
chronic schizophrenia who have had the illness for over a decade on 
average, indicating longstanding upregulation of DHEA, which is in 
support of other reports of elevated DHEA in chronically ill patients (di 
Michele et al., 2005). As DHEA levels are also elevated in drug-naive 
patients (Beyazyüz et al., 2014), this suggests that increased DHEA is 
related to pathology and not merely a result of antipsychotic use. To 
support this, we did not find a relationship between mean daily CPZ 
equivalent dose and DHEA levels. However, a recent study found that 
levels of DHEA-sulfate and cortisol differ between patients with and 
without metabolic syndrome (Boiko et al., 2020), which has been linked 
to antipsychotics (Mitchell et al., 2013). Although we did not find any 
relationships of BMI to cortisol or DHEA in our patient sample, we did 
not measure DHEA-sulfate in particular and cannot rule out the possi-
bility that changes in hormones levels may in part reveal changes in 
metabolic-related activity known to occur in chronically ill patients 
receiving antipsychotics for long periods of time. Our measurement of 
hormones at a single-time point may be influenced by other 
Fig. 1. Patients with schizophrenia displayed (a) significantly increased serum DHEA, (b) no difference in circulating cortisol levels, and (c) significantly decreased 
cortisol/DHEA ratios as compared with healthy controls. Plots reflect raw, age-adjusted means and standard error. (*p < 0.05, **p < 0.01) 
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stress-related (e.g. chronic stress related to schizophrenia and acute 
stress attributed to blood draw) and non-stress related (e.g. time of blood 
drawn relative to wake time, physical activity, number of hours slept, 
iatrogenic effects) factors (Chida and Steptoe, 2009; Hucklebridge et al., 
2005). Repeated measures of hormones as opposed to a single mea-
surement, in addition to assessments (e.g., how stressed the participant 
feels about having their blood drawn, lifetime exposure to stressful 
events, etc.), would help pinpoint potential contributors of stress more 
precisely. 
DHEA may exert some of its actions through conversion into its 
potent sex steroid metabolites (i.e. estrogen and testosterone) and acti-
vation of androgen or estrogen receptors (Chen et al., 2005). In relation 
to this, downstream abnormalities in sex steroids could have implica-
tions for DHEA. Indeed, low circulating levels of testosterone have been 
found in men with schizophrenia (Misiak et al., 2018), which may 
initiate a positive feedback loop, prompting increased production of 
DHEA. While differences in DHEA’s metabolites have been reported in 
schizophrenia patients varying by sex (e.g. with decreased testosterone 
in male patients (Misiak et al., 2018; Owens et al., 2018) and increased 
testosterone in female patients (Misiak et al., 2018)), it is unclear if sex 
also plays a moderating role in circulating DHEA in people with 
schizophrenia. In healthy individuals, previous evidence suggests that 
serum DHEA levels fluctuate in a non-linear manner with age differen-
tially in males and females (Sulcová et al., 1997). One study has reported 
decreased serum levels of DHEA in only males with schizophrenia 
(Huang et al., 2017). Although we did not find significant effects of sex 
in our sample, future studies assessing how sex may influence DHEA and 
cortisol/DHEA levels in people with schizophrenia across the lifespan 
are warranted. 
Our finding of decreased cortisol/DHEA ratios in people with 
schizophrenia is counter to one report of increased (Ritsner et al., 2004) 
and findings of no difference (Gallagher et al., 2007; Garner et al., 2011) 
in cortisol/DHEA ratios in patients. The combination of our findings - 
increased DHEA levels, a positive correlation between DHEA and 
cortisol reflecting DHEA-related anti-glucocorticoid activity, and the 
absence of hypercortisolemia - may suggest that in addition to cortisol, 
other factors are maintaining DHEA upregulation in schizophrenia, 
resulting in a low cortisol/DHEA ratio relative to controls. Increased 
DHEA may remain in circulation as a compensatory consequence of 
chronic stressors such as oxidative stress and increased inflammation in 
the body and brain, which are strongly implicated in schizophrenia 
(Fillman et al., 2013; Flatow et al., 2013). Oxidative damage has been 
found in the hippocampus (Che et al., 2010) and DLPFC (Gawryluk 
et al., 2011) in individuals with schizophrenia. Furthermore, adminis-
tration of agents known to induce oxidative stress results in increased 
DHEA formation in the brain (Brown et al., 2003) and periphery 
(Rammouz et al., 2011). Therefore, our finding of elevated peripheral 
DHEA may also be indicative of an attempt at neuroprotection against 
oxidative stressors in people with schizophrenia. Our group has reported 
that IL-1β, IL-6 and IL-8 mRNA are upregulated in the DLPFC and pe-
riphery, within a subset of people with schizophrenia (Fillman et al., 
2013; Fillman et al., 2016). DHEA decreases pro-inflammatory cytokine 
production in vivo (Kimura et al., 1998) and in vitro (Straub et al., 1998); 
therefore, increased DHEA levels in schizophrenia may represent an 
Fig. 2. Cortisol/DHEA ratios were significantly, negatively correlated with bilateral (a) hippocampal and (b) DLPFC volume in patients. The 95% confidence interval 
of the regression line is shaded in pink. Plots are residual plots, covarying for age. 
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increase in anti-inflammatory processes and reflect the body’s effort to 
protect against inflammation. Another possible mechanism contributing 
to lower cortisol/DHEA ratios is a blunted cortisol response to stress, 
which has been found in people with schizophrenia by multiple groups 
(Jansen et al., 2000). Reduced production of cortisol or the preferential 
production of one hormone over the other could account for our finding 
of decreased cortisol/DHEA ratios in the schizophrenia group. On the 
whole, owing to the neuroprotective properties of DHEA, our results 
support the hypothesis that higher levels of DHEA in schizophrenia 
could reflect a compensatory upregulation against multiple factors and, 
similarly, that decreased cortisol/DHEA ratios relative to controls may 
reflect prolonged upregulation of a neuroprotective response and/or 
blunted cortisol response. 
Importantly, as both increased DHEA and decreased cortisol/DHEA 
ratios have been found in people with post-traumatic stress disorder 
(Yehuda et al., 2006), findings from our study may not reflect 
schizophrenia-specific biomarkers per se, but instead demonstrate that 
deviations from normal HPA axis activity can be captured across diverse 
stress-related conditions. Although we measured levels of hormones as 
markers of HPA activation in the blood, the clinical relevance of our 
findings may depend upon the likelihood that the peripheral levels 
mirror the levels of these hormones in the brain. We have previously 
found parallel transcriptional changes in stress responsive genes in the 
brain and blood. In particular, reduced glucocorticoid receptor mRNA 
(Sinclair et al., 2012a; Sinclair et al., 2011; Sinclair et al., 2012b; 
Webster et al., 2002) and increased FKBP5 mRNA (Lee et al., 2019; 
Sinclair et al., 2013), which likely relates to greater stress levels or 
repeated stress exposure (Matosin et al., 2018), are found in schizo-
phrenia. Indeed, changes in the stress responsive genes occur at the 
mRNA and protein level in the blood and in multiple brain regions in 
people with schizophrenia, suggesting that changes in stress-responsive 
genes may be widespread and systemic. Both cortisol and DHEA can 
cross the blood-brain barrier and studies have found that, across in-
dividuals within studies, cortisol in CSF correlates with circulating 
cortisol levels (r = 0.89, p < 0.001) (Carroll et al., 1976) and DHEA in 
CSF correlates with serum DHEA levels (r = 0.65, p < 0.01) (Guazzo 
et al., 1996). However, we must also consider that while the blood-brain 
barrier is selectively permeable to steroid hormones via transmembrane 
diffusion, the ease at which they penetrate may be dependent on the 
level and effectiveness of hormone carrier proteins (Mason et al., 2010; 
Pardridge and Mietus, 1979). Collectively, these lines of evidence enable 
us to make inferences on brain hormone levels based on blood markers, 
at least to some degree, and suggest that measurement of hormone 
transporters in brain endothelial cells may be of interest. 
Previous studies examining cortisol and DHEA in schizophrenia have 
only assessed behavioral clinical phenotypes. This study is the first to 
report a relationship between cortisol/DHEA ratios and brain volume 
reductions in people with schizophrenia. We should consider the im-
plications of our parallel, yet seemingly opposed, findings in patients of 
(1) an inverse relationship between cortisol/DHEA and brain volume 
and (2) decreased cortisol/DHEA compared to controls. It is not intuitive 
as to why elevated cortisol/DHEA ratios relate to reduced brain volume 
in patients, while patients have lower ratios and smaller brain volume 
relative to the controls. One explanation may be that the hormone levels 
in each diagnostic group are influenced by different biological processes 
such that the comparisons of the ratios across diagnostic groups is not 
linear. For example, it may be that baseline regulation of cortisol and 
DHEA differ in patients versus controls. Low/normal cortisol levels in 
patients may reflect blunting of the cortisol response due to adaptation 
of the HPA axis from extended periods of stress (Bunea et al., 2017); 
whereas, low/normal cortisol in healthy controls who experience less 
stress could relate to better regulation of cortisol. In patients, greater 
lifetime exposure to stress may yield blunted cortisol, along with 
heightened DHEA (Lam et al., 2019), perhaps indicating efforts to 
combat stress and related brain tissue damage, which would not be 
necessary in healthy people. This would then yield decreased 
cortisol/DHEA ratios in patients relative to controls and explain why 
elevated cortisol/DHEA corresponded to reduced brain volume in pa-
tients only. Thus, cortisol/DHEA may serve as a neurotoxicity marker 
related to brain volume loss such that elevated cortisol/DHEA ratios are 
harmful to the brains of patients with schizophrenia while such a rela-
tionship is not clearly identifiable in the healthy brain. 
All things considered, our findings demonstrate that DHEA may help 
mediate brain vulnerability in mental illness and tissue volume loss 
associated with schizophrenia to a certain degree. Being as how our 
finding was unique to the patient group may suggest that DHEA’s neu-
roprotective effects are heightened under stress-related conditions, 
which is supported by findings by Jin and colleagues of a negative 
correlation between cortisol/DHEA ratios and hippocampal volume in 
people with major depressive disorder but not in controls (Jin et al., 
2016). We did not find a significant relationship between serum cortisol 
levels and brain volume, which is consistent with some (Jin et al., 2016) 
but not all (Mondelli et al., 2010b) studies of mental illness. 
Between-study discrepancies may be attributed to study-specific differ-
ences in medication, serum collection and assay, imaging acquisition 
protocols and/or statistical methods. Similarly to previous work that 
reported a near-significant positive correlation between DHEA and 
hippocampal volume in their sample of depressed patients (Jin et al., 
2016), we found a trend towards a significant positive correlation be-
tween DHEA and hippocampal volume in people with schizophrenia. 
However, in both studies, the ratio of cortisol/DHEA had stronger as-
sociations with brain volume than DHEA alone in patients. This supports 
the hypothesis that the ratio of cortisol to DHEA is more informative 
than their absolute concentrations alone (Wolkowitz et al., 2001), and 
that DHEA activity may be more influential in the hippocampus when 
interacting with cortisol activity. As the hippocampus and DLPFC are 
vulnerable targets of stress-related pathology (Sinclair et al., 2011; 
Webster et al., 2002) and reduced hippocampal volume has been 
exhibited in other disorders in which stress plays a role including 
post-traumatic stress disorder (Gurvits et al., 1996), Cushing’s syndrome 
(Starkman et al., 1992) and depression (Sheline et al., 1999), identifying 
steroid markers that correspond with brain volumetric reduction may 
help us better understand the neurobiological basis for brain tissue loss 
across human disease. 
Our study has some limitations. All patients in our sample were 
receiving antipsychotic medication. There is some evidence from animal 
models suggesting that clozapine is associated with decreases in DHEA 
(Nechmad et al., 2003). If this occurs in humans, then such an effect 
would lower DHEA levels in our patient sample; yet, we were still able to 
detect significantly elevated DHEA levels and we also did not find an 
association between circulating DHEA and CPZ equivalents. Addition-
ally, the present study included measures of DHEA and not 
DHEA-sulfate, which should also be considered in future studies as they 
may differ in their circulating levels and relationship to symptomatology 
(Misiak et al., 2018; Strous et al., 2004). Lastly, DHEA is tightly linked 
with age such that concentrations markedly decrease around the early 
thirties (Sulcova et al., 1997). Our patient sample was nearly four years 
older on average than the control sample (mean ages were 35.7 vs 31.8 
years, respectively), thus their DHEA levels may have started to decline 
for a longer period of time which could be a confounding factor in our 
analyses. However, despite the age difference, we found significantly 
increased DHEA levels in people with schizophrenia relative to the 
controls and we adjusted for age in all analyses involving hormones. 
To conclude, this is the largest study to date to examine circulating 
levels of DHEA and cortisol/DHEA ratios in schizophrenia and the first 
study to link the cortisol/DHEA ratio with reduced brain volume in 
schizophrenia. Our findings add to the multiple lines of direct and in-
direct evidence supporting the intriguing phenomenon that a neuro-
protective hormone, DHEA, is upregulated in some people with 
schizophrenia. Whether this truly serves as an effective compensatory 
mechanism has yet to be confirmed. Our findings also suggest that 
studying cortisol and DHEA in concert may serve as a potential 
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biomarker of stress-related brain tissue loss in people with schizo-
phrenia. Altogether, these results further implicate the role of DHEA and 
HPA axis dysfunction in the pathophysiology of schizophrenia. 
Funding and Disclosure 
This work was supported by grant 568807 from the National Health 
and Medical Research Council (NHMRC) of Australia, the NSW Ministry 
of Health, Office of Health and Medical Research, the Pratt Foundation, 
Ramsay Health Care and the Viertel Charitable Foundation. CSW is a 
recipient of a National Health and Medical Research Council (Australia) 
Principal Research Fellowship (PRF) (#1117079). The authors declare 
no conflict of interest in relation to this work. 
Author contributions 
EJ was involved in the conception of the project, analyzed the data 
and wrote and edited the manuscript. CSW was involved in the 
conception of the project, assisted with protocol and ethics construction, 
supervised the project in relation to data collection, management, 
monitoring and analysis, and edited the manuscript. TP, CW, DJH and 
RD coordinated and performed the blood assays and edited the manu-
script. MOD performed the medical exams, assisted with recruitment 
and edited the manuscript. DL and RL performed and reviewed SCIDs, 
assisted with the recruitment, performed medical exams and edited the 
manuscript. CG supervised the Adelaide site, performed and reviewed 
SCIDs, assisted with recruitment, performed medical exams and edited 
the manuscript. TW was involved in the conception of the project, wrote 
and revised the protocol and ethics, coordinated the project, supervised 
the project in relation to data collection, management, monitoring and 
analysis, performed SCIDs and edited the manuscript. 
Declaration of Competing Interest 
The authors declare no conflict of interest in relation to this work. 
Acknowledgements 
We thank Daniel Pellen, Loretta Moore, Ans Vercammen, Nick Vella, 
Ashley Skilleter, Alice Rothwell and Richard Morris for screening par-
ticipants, administering assessments, acquiring imaging data and data 
entry. We also sincerely thank the participants in this study. 
Appendix A. Supplementary data 
Supplementary material related to this article can be found, in the 
online version, at doi:https://doi.org/10.1016/j.psyneuen.2020.10491 
6. 
References 
Bastianetto, S., Ramassamy, C., Poirier, J., Quirion, R., 1999. Dehydroepiandrosterone 
(DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res 
Mol Brain Res 66, 35–41. 
Bates, D., Bolker B, M.M., Walker, S., 2015. Fitting Linear Mixed-Effects Models Using 
lme4. Journal of Statistical Software 67, 1–48. 
Beyazyüz, M., Albayrak, Y., Beyazyüz, E., Ünsal, C., Göka, E., 2014. Increased serum 
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